Press release
September 11, 2014
Corindus Vascular Robotics Highlights Radiation Reduction at TCT Meeting

Company to host breakfast symposium presentation on radiation safety in the cath lab and robotic precision

Waltham, MA – September 11, 2014Corindus Vascular Robotics, Inc. [OTCQB: CVRS], a leading developer of precision vascular robotics, will showcase its CorPath©Vascular Robotic System during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting, September 13 – 17 in Washington, D.C. Throughout the meeting, Corindus will highlight occupational safety and robotic precision during percutaneous coronary intervention (PCI) procedures, including radiation exposure reduction by robotic-assisted PCI.

Sessions highlighting the CorPath System:

  • September 13 – Poster reviewing complex PCI performed with robotic-assistance (5:00-7:00pm)
  • September 14 – Live Robotic-assisted PCI case presentation in Main Arena (11:00am)
  • September 15 – CorPath discussed during Session 1: Cath Lab Technology Evolution: Imaging Integration and Radiation Reduction (2:00-3:08pm)
  • September 16 – Corindus sponsored breakfast symposium “Robotic PCI: Precision and Protection from Occupational Hazards” (6:30-8:00am)
  • CorPath System in a simulator environment throughout the meeting at the Corindus Vascular Robotics Booth #1342 in the Expo hall
  • Daily "Hot Topic Lunch" sessions to discuss radiation control will be held in room 142.

The Corindus CorPath System is the first FDA-approved medical device to bring robotic precision and accuracy to help optimize clinical outcomes during coronary angioplasties. Additionally, the CorPath System reduces radiation exposure for the interventional cardiologist.

“Radiation poses a risk to the health and safety of interventional cardiologists today; however, use of the CorPath System has proven to reduce radiation exposure while providing robotic precision during PCI,” said David Handler, President and CEO of Corindus Vascular Robotics. “Radiation exposure as an occupational hazard among interventional cardiologists is becoming a growing concern that must be addressed, and Corindus is dedicated to advocating for the safety of these physicians and their patients. TCT provides an ideal forum for us to bring these issues to the forefront.”

Recent studies and published articles pointing to the risks associated with traditional PCI procedures include:

  • A study by Venneri, et al. highlighting that interventional cardiologists experience the highest amounts of radiation exposure of any medical professionals.
  • A study by Roguin, et al. which linked radiation exposure to the prevalence of brain tumors on the left-side of the brain. The study found that 86% of interventional cardiologists who self-reported brain tumors had the malignancy on the left side, which is the side closest to the x-ray source during procedures.
  • A study reported by Vano, et al reveals that radiation exposure has led to 50% of interventional cardiologists displaying significant posterior subcapsular lens changes, a precursor to cataracts, which are typical of ionizing radiation exposure.

For more information on the symposium, “Robotic PCI: Precision and Protection from Occupational Hazards,” click here.

TCT Meeting attendees can register here to use the CorPath System in a simulator environment at the Corindus Vascular Robotics Booth #1342.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window